Literature DB >> 10078629

Addition of chemotherapy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials.

J D Cox1, C B Scott, R W Byhardt, B Emami, A H Russell, K K Fu, M B Parliament, R Komaki, L E Gaspar.   

Abstract

PURPOSE: To evaluate the influence of cell type within non-small cell carcinoma of lung (NSCCL) on failure patterns when chemotherapy (CT) is combined with radiation therapy (RT). METHODS AND MATERIALS: Data from 4 RTOG studies including 1415 patients treated with RT alone, and 5 RTOG studies including 350 patients also treated with chemotherapy (RT + CT) were analyzed. Patterns of progression were evaluated for squamous cell carcinoma (SQ) (n = 946), adenocarcinoma (AD) (n = 532) and large cell carcinoma (LC) (n = 287).
RESULTS: When treated with RT alone, SQ was more likely to progress at the primary site than LC (26% vs. 20%, p = 0.05). AD and LC were more likely to progress in the brain than SQ (20% and 18% vs. 11%, p = 0.0001 and 0.011, respectively). No differences were found in intrathoracic and distant metastasis by cell type. When treated with RT + CT, AD was less likely to progress at the primary than either SQ or LC (23% vs. 34% and 40%, respectively; p = 0.057 and 0.035). AD was more likely than SQ to metastasize to the brain (16% vs. 8%, p = 0.03), and other distant sites (26% vs. 14%,p = 0.019). No differences were found in intrathoracic metastasis. LC progressed at the primary site more often with RT + CT than with RT alone (40% vs. 20%, p = 0.036). Death with no clinical progression was more likely with SQ than AD or LC for RT alone and RT + CT (p < 0.01). Brain metastasis was altered little by the addition of CT, but other distant metastases were significantly decreased (p < 0.001) in all cell types by the addition of CT.
CONCLUSION: CT, although effective in reducing distant metastasis in all types of NSCCL, has different effects on the primary tumor by cell type, and has no effect on brain metastasis or death with no progression. Different treatment strategies should be considered for the different cell types to advance progress with RT + CT in NSCCL.

Entities:  

Mesh:

Year:  1999        PMID: 10078629     DOI: 10.1016/s0360-3016(98)00429-5

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  32 in total

1.  The Thr300Ala variant of ATG16L1 is associated with decreased risk of brain metastasis in patients with non-small cell lung cancer.

Authors:  Qian-Xia Li; Xiao Zhou; Ting-Ting Huang; Yang Tang; Bo Liu; Ping Peng; Li Sun; Yi-Hua Wang; Xiang-Lin Yuan
Journal:  Autophagy       Date:  2017-04-25       Impact factor: 16.016

2.  The molecular genomics of metastatic brain tumours.

Authors:  A Bollig-Fischer; Sk Michelhaugh; R Ali-Fehmi; S Mittal
Journal:  OA Mol Oncol       Date:  2013-04-01

Review 3.  Radiation therapy in the prevention of brain metastases.

Authors:  Joseph A Bovi; Julia White
Journal:  Curr Oncol Rep       Date:  2012-02       Impact factor: 5.075

4.  Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-small-cell lung cancer: neurocognitive and quality-of-life analysis.

Authors:  Alexander Sun; Kyounghwa Bae; Elizabeth M Gore; Benjamin Movsas; Stuart J Wong; Christina A Meyers; James A Bonner; Steven E Schild; Laurie E Gaspar; Jeffery A Bogart; Maria Werner-Wasik; Hak Choy
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

5.  Radiotherapy alone versus radiochemotherapy in patients with stage IIIA adenocarcinoma (ADC) of the lung.

Authors:  B Jeremić; B Miličić; S Milisavljević
Journal:  Clin Transl Oncol       Date:  2013-01-29       Impact factor: 3.405

6.  Impact of early tumor reduction on outcome differs by histological subtype in stage III non-small-cell lung cancer treated with definitive radiotherapy.

Authors:  Hiromitsu Kanzaki; Masaaki Kataoka; Atsushi Nishikawa; Kotaro Uwatsu; Kei Nagasaki; Noriko Nishijima; Takashi Ochi; Teruhito Mochizuki
Journal:  Int J Clin Oncol       Date:  2016-04-28       Impact factor: 3.402

Review 7.  Prophylactic cranial irradiation: recent outcomes and innovations.

Authors:  James W Snider; Vinai Gondi; Paul D Brown; Wolfgang Tome; Minesh P Mehta
Journal:  CNS Oncol       Date:  2014-05

8.  Outcomes research in cancer clinical trial cooperative groups: the RTOG model.

Authors:  D W Bruner; B Movsas; A Konski; M Roach; M Bondy; C Scarintino; C Scott; W Curran
Journal:  Qual Life Res       Date:  2004-08       Impact factor: 4.147

9.  Prophylactic cranial irradiation in locally advanced non-small cell lung cancer: outcome of recursive partitioning analysis group 1 patients.

Authors:  Ali Aydin Yavuz; Erkan Topkan; Cem Onal; Melek Nur Yavuz
Journal:  J Exp Clin Cancer Res       Date:  2008-12-04

10.  Diagnostic efficacy of PET/CT plus brain MR imaging for detection of extrathoracic metastases in patients with lung adenocarcinoma.

Authors:  Ho Yun Lee; Kyung Soo Lee; Byung-Tae Kim; Young-Seok Cho; Eun Jeong Lee; Chin A Yi; Myung Jin Chung; Tae Sung Kim; O Jung Kwon; Hojoong Kim
Journal:  J Korean Med Sci       Date:  2009-11-09       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.